series-a
Stage
1
Investors
About
Vima Therapeutics develops oral therapies targeting muscarinic cholinergic receptors to treat movement disorders such as dystonia and Parkinson's disease.
Explore Vima Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.